GenScript ProBio (a global one-stop contract development and manufacturing organisation or CDMO from GenScript Group) has announced a strategic collaboration with Hibiocy Co., a private corporation based in Bangkok, Thailand, to accelerate a respiratory-care medical device, COVITRAP which contains human antibody for COVID-19.

COVITRAP is a nasal spray which is capable of preventing the COVID-19 virus from attaching to the internal surfaces of the nasal cavity, thus reducing the viral load in the cavity. COVITRAP was successfully approved by Thai FDA and was officially launched in Thailand market. Hibiocy is working to launch the COVITRAP nasal spray device in other countries as well. GenScript ProBio will be the exclusive service partner for the upcoming commercial manufacturing.

Aside from the COVITRAP project, both parties are dedicated to set off a future long term collaboration for new product and manufacturing in near future.

Johnson Wang, President of GenScript Asia Pacific said, "We believe the COVID-19 nasal spray device represents a promising approach to combating the novel coronavirus pandemic and will bring benefit to the public. This collaboration with Hibiocy brings together two companies dedicated to the fight against COVID-19 to utilize our joint capabilities in complementary and synergistic ways to address this difficult global health challenge."

Image caption- Worrawan Chaikamnerd, CEO at Hibiocy and KISS (left) and Johnson Wang, President of GenScript Asia Pacific (right)